Malaria vaccine live attenuated - Sanaria

Drug Profile

Malaria vaccine live attenuated - Sanaria

Alternative Names: Pf delta b9 delta Slarp; PfSPZ malaria vaccine live attenuated - Sanaria; PfSPZ Vaccine - Sanaria; PfSPZ-GA1; Pf∆b9∆Slarp; Plasmodium falciparum sporozoite vaccine live attenuated - Sanaria; Sanaria PfSPZ Vaccine

Latest Information Update: 31 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanaria
  • Developer National Institute of Allergy and Infectious Diseases; PATH; Sanaria
  • Class Attenuated vaccines; Malaria vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Falciparum malaria

Most Recent Events

  • 01 Aug 2018 Sanaria initiates enrolment in a phase I trial in Falciparum malaria (Prevention) in Equatorial Guinea (IV) (NCT03590340)
  • 18 Jul 2018 Sanaria plans a phase I trial for Malaria in healthy volunteers in Equatorial Guinea (NCT03590340)
  • 14 Jun 2018 Phase-II clinical trials in Falciparum malaria (Prevention, In children) in Gabon (IV) (NCT03521973)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top